ATE258436T1 - Verwendung von indol-3-essigsäurederivaten in der therapie - Google Patents

Verwendung von indol-3-essigsäurederivaten in der therapie

Info

Publication number
ATE258436T1
ATE258436T1 AT01945476T AT01945476T ATE258436T1 AT E258436 T1 ATE258436 T1 AT E258436T1 AT 01945476 T AT01945476 T AT 01945476T AT 01945476 T AT01945476 T AT 01945476T AT E258436 T1 ATE258436 T1 AT E258436T1
Authority
AT
Austria
Prior art keywords
sub
groups
therapy
indole
acetic acid
Prior art date
Application number
AT01945476T
Other languages
English (en)
Inventor
Peter Wardman
Lisa K Folkes
Gabriele U Dachs
Sharon Rossiter
Olga Greco
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of ATE258436T1 publication Critical patent/ATE258436T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01945476T 2000-06-30 2001-06-28 Verwendung von indol-3-essigsäurederivaten in der therapie ATE258436T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0016162.0A GB0016162D0 (en) 2000-06-30 2000-06-30 Indole-3-acetic acid derivatives
PCT/GB2001/002872 WO2002002110A1 (en) 2000-06-30 2001-06-28 Use of indole-3-acetic acid derivatives in medicine

Publications (1)

Publication Number Publication Date
ATE258436T1 true ATE258436T1 (de) 2004-02-15

Family

ID=9894821

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01945476T ATE258436T1 (de) 2000-06-30 2001-06-28 Verwendung von indol-3-essigsäurederivaten in der therapie

Country Status (8)

Country Link
US (1) US6890948B1 (de)
EP (1) EP1296676B1 (de)
AT (1) ATE258436T1 (de)
AU (1) AU2001267690A1 (de)
DE (1) DE60101914T2 (de)
ES (1) ES2215138T3 (de)
GB (1) GB0016162D0 (de)
WO (1) WO2002002110A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078126A2 (en) 2003-02-28 2004-09-16 Oxigene, Inc. Compositions and methods with enhanced therapeutic activity
ES2459371T3 (es) 2006-01-05 2014-05-09 Lg Electronics Inc. Transmisión de información en un sistema de comunicaciones móviles
KR100773475B1 (ko) 2006-07-07 2007-11-05 주식회사 웰스킨 인돌-3-아세트산을 포함하는 광감작제, 및 이를 포함하는광역학적 치료용 키트
US8580192B2 (en) 2006-10-31 2013-11-12 Ethicon, Inc. Sterilization of polymeric materials
KR20090001013A (ko) * 2007-06-29 2009-01-08 주식회사 웰스킨 인돌-3-알킬카복실산을 함유하는 여드름 치료제 및 피지분비 억제제, 및 이를 포함하는 광역학적 치료용 키트
KR101089750B1 (ko) 2009-11-25 2011-12-07 중앙대학교 산학협력단 5―히드록시인돌초산을 포함하는 광감작용 조성물 및 이를 포함하는 암의 광역학 치료용 조성물
US8748446B2 (en) 2012-03-03 2014-06-10 Nanoquantum Sciences, Inc. Halogenated compounds for photodynamic therapy
CN105037239B (zh) * 2015-07-21 2018-04-06 苏州卡耐博生物技术有限公司 一种4‑氯吲哚‑3‑乙酸的制备方法
EP3710481A4 (de) * 2017-11-16 2021-08-18 Antigenesis LLC Systeme und verfahren für lysosominduzierten tod immunogener zellen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA957281A (en) * 1970-02-03 1974-11-05 Nathan N. Share Pharmaceutical compositions containing indole-3-acetic acid derivatives as a skeletal muscle stimulant
US3901914A (en) * 1973-11-01 1975-08-26 Merck & Co Inc 1-(substituted phosphinothioyl, phosphinyl or phosphino)-substituted indole-3-acetic acids
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
ZA939516B (en) * 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
GB9609641D0 (en) * 1996-05-09 1996-07-10 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
AU2001267690A1 (en) 2002-01-14
US6890948B1 (en) 2005-05-10
DE60101914T2 (de) 2004-10-28
ES2215138T3 (es) 2004-10-01
WO2002002110A1 (en) 2002-01-10
GB0016162D0 (en) 2000-08-23
EP1296676A1 (de) 2003-04-02
EP1296676B1 (de) 2004-01-28
DE60101914D1 (de) 2004-03-04

Similar Documents

Publication Publication Date Title
ATE283271T1 (de) Porphyrin derivate, ihre verwendung in der photodynamischen therapie und diese enthaltende medizinische geräte
FI901739A0 (fi) Bensimidazoler, dessa foereningar innehaollande laekemedel och foerfarande foer deras framstaellning.
TR200001530T2 (tr) Gastrik asit salgılamasının önlenmesi için heterosiklik bileşimler
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
ATE276237T1 (de) 2-phenylbenzimidazolsulfonsäuren als uv-b-filter
DE69918404D1 (de) Aminophenoxyessigsäure derivate als neuroschützende mittel
DE60003021D1 (de) Benzoesäureesterderivate, diese enthaltende zusammenstellungen und deren anwendung
AU6894800A (en) Caspase inhibitors and uses thereof
EE200200148A (et) Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
ATE218571T1 (de) Proteinkinase c-inhibitoren zur behandlung von neurologischen erkrankungen
TR199902060T2 (xx) Gastrik asit salg�lanmas�n�n inhibisyonu i�in bile�ikler.
ATE258436T1 (de) Verwendung von indol-3-essigsäurederivaten in der therapie
ATE163007T1 (de) Neue vitamin d derivate
TR28332A (tr) Arilasetik asit türevleri.
KR910000637A (ko) 피롤 유도체, 이의 제조 방법 및 약제학적 활성화합물로서의 이의 용도
TR199901416T2 (xx) Heterosiklik karbonikasit t�revleri.
DE69909811D1 (de) Substituierte isoxazolylthiophenverbindungen
DK0514942T3 (da) Hidtil ukendte benzopyranderivater og fremgangsmåder til fremstilling deraf
ATE18761T1 (de) Carbamoyloxybenzhydrol-derivate, ihre herstellung und ihre pharmazeutische zusammensetzungen.
FR2757164B1 (fr) Nouveaux derives de n-benzylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE60122350D1 (de) Benzoesaüre derivate und deren verwendung
ATE218138T1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung
ATE230273T1 (de) Verwendung von deltorphin zur behandlung von zytokin-vermittelter leberschädigung
DE69527854D1 (de) Derivate substituierter amidinonaphthylester

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties